Regulatory
October 28, 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
October 23, 2024
The Extraordinary General Meeting of Active Biotech was held on October 23, 2024. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved to amend the Articles of Association, whereby the limits for the company’s share capital are changed to not less than…
October 21, 2024
THIRD QUARTER IN BRIEF Active Biotech entered agreement with MD Anderson for a clinical study of tasquinimod in myelofibrosis (July 1) Active Biotech provided an update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma (July 15) Active Biotech reported intriguing intraocular concentrations achieved in a…
October 2, 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
September 24, 2024
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Extraordinary General Meeting of shareholders to be held on Wednesday, October 23, 2024 at 11 a.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
September 23, 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
September 10, 2024
Lund, September 10 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to the ongoing clinical phase I biodistribution study of laquinimod eye drops in patients undergoing vitrectomy. A proprietary formulation of laquinimod for corneal application was developed, taking the specific physico-chemical characteristics of this agent into account,…
August 22, 2024
SECOND QUARTER IN BRIEF Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3) Active Biotech acquired exclusive rights to patents of tasquinimod in combination therapy in multiple myeloma (May 22) Clinical activity and safety of naptumomab and docetaxel in non-small cell lung cancer…
July 15, 2024
Lund, July 15 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to a clinical study of tasquinimod in patients with relapsed refractory multiple myeloma (RRMM) being conducted at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia. The study is ongoing in its expansion cohort…
May 31, 2024
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, the last trading day of the month, there are in total 361,813,142 shares and votes in Active Biotech. For…
May 28, 2024
Lund, May 28, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces today that NeoTX Therapeutics, exclusive licensee of naptumomab estafenatox (naptumomab, NAP) from Active Biotech, will present initial results from phase IIa trial with NAP and docetaxel in advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) patients, at the American Society of…
May 22, 2024
The Annual General Meeting of Active Biotech was held on May 22, 2024. The following main resolutions were passed.In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2023, and that the Company’s accumulated loss shall be carried forward.…
May 22, 2024
Lund, May 22, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces it has entered into an exclusive license agreement with the Wistar Institute of Anatomy and Biology (“Wistar”), Philadelphia, US for the global rights to Wistars interest in the joint IP relating to the use of tasquinimod in combination…
May 8, 2024
FIRST QUARTER IN BRIEF Preparations ongoing for start of the clinical proof of concept studies with tasquinimod in myelofibrosis The expansion cohort of the study in multiple myeloma is ongoing according to plan EVENTS AFTER THE END OF THE PERIOD Start of enrollment to the clinical phase I biodistribution study…
April 23, 2024
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 22, 2024 at 5 p.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
April 22, 2024
Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2023 now is available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. “I am very pleased with the progress of our projects in 2023. We are strengthened in our belief that our projects have the potential to…
February 8, 2024
FOURTH QUARTER IN BRIEF Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis (December 1) Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod (December 5) Active Biotech announces outcome of the Company’s rights issue (December 6) Preclinical data of…
December 29, 2023
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue. Today, the last trading day of the month, there are in total 361,739,047 shares and votes in Active Biotech. For further information, please contact: Helén Tuvesson, CEO, +46 46…
December 6, 2023
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
December 1, 2023
In accordance with a decision made by the Annual General Meeting held on May 24, 2023, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2023, and the Chairman of the Board. If a shareholder does not exercise its right…
November 29, 2023
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
November 13, 2023
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
November 9, 2023
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
November 9, 2023
THIRD QUARTER IN BRIEF Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31) Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11) Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting…
August 24, 2023
SECOND QUARTER IN BRIEF Safety and preliminary efficacy of naptumomab in combination with durvalumab presented at AACR 2023 (April 19) Positive interim data from the ongoing study of tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma presented at ASCO 2023 (May 26) Positive safety and tolerability in…
May 24, 2023
The Annual General Meeting of Active Biotech was held on May 24, 2023. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2022, and that the Company’s accumulated loss shall be carried…
May 4, 2023
FIRST QUARTER IN BRIEF Active Biotech confirmed positive clinical safety profile of laquinimod eye drops (January 30) Active Biotech published new preclinical data highlighting the mechanisms behind the anti-tumor activity of tasquinimod in hematological malignances New preclinical data on naptumomab published EVENTS AFTER THE END OF THE PERIOD Safety and…
April 26, 2023
Active Biotech’s Annual Report 2022 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. For further information, please contact: Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.comHans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com About Active Biotech Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is…
April 25, 2023
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 24, 2023 at 5 p.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
March 31, 2023
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, the last trading day of the month, there are in total 265,144,687 shares and votes in Active Biotech. For…
February 9, 2023
FOURTH QUARTER IN BRIEF Active Biotech further strengthened the patent protection for laquinimod in eye disorders with a granted patent in US (Oct 24) Preclinical data with tasquinimod in MDS presented at ASH 2022 (Dec 13) Phase I Multiple dose study of laquinimod recruited final patient OTHER SIGNIFICANT EVENTS JAN…
January 30, 2023
Lund, January 30, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced the completion of the phase I clinical study testing the safety and tolerability of the newly developed laquinimod eye drop formulation in healthy subjects. According to the results, the eye drop was safe and well tolerated both at…
December 5, 2022
In accordance with a decision made by the Annual General Meeting held on May 19, 2022, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2022, and the Chairman of the Board. If a shareholder does not exercise its right…
November 3, 2022
THIRD QUARTER IN BRIEF Based on the authorization from the general meeting, the board of directors resolved to carry out a rights issue of approximately SEK 55 million to secure financing of the ongoing and planned development programs (Aug 4) The first part of the multiple dose of laquinimod eye…
October 24, 2022
Lund, October 24, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization. The patent will be issued on 25 October, 2022, under…
September 30, 2022
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue. Today, the last trading day of the month, there are in total 264,886,797 shares and votes in Active Biotech. For further information, please contact: Helén Tuvesson, CEO, +46 46…
September 7, 2022
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW Active…
August 16, 2022
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW The…
August 4, 2022
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW The board…
August 4, 2022
SECOND QUARTER IN BRIEF Laquinimod eye drop phase I single ascending-dose part in healthy subjects was completed without reported safety concerns, multiple-dose part started Active Biotech strengthened the patent protection for laquinimod in eye disorders (April 26) FDA granted Orphan Drug Designation for tasquinimod in myelofibrosis (May 18) Successful completion…
June 1, 2022
Lund, June 1, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox (NAP, naptumomab), in combination with docetaxel in patients with advanced or metastatic non-small cell lung…
May 18, 2022
Lund May 18, 2022 – Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for…
April 28, 2022
Active Biotech’s Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active Biotech AB (publ) Helén Tuvesson CEO For further information, please contact: Helén Tuvesson, CEO, tel. +46 46 19 21 56, helen.tuvesson@activebiotech.com Hans Kolam, CFO,…
April 26, 2022
Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization. The patent will be granted on May 11, 2022, under…
April 21, 2022
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01) First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07) Active Biotech entered into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis (Feb 9) EVENTS…
April 20, 2022
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday, May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting…
March 31, 2022
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, the last trading day of the month, there are in total 218,054,720 shares and votes in Active Biotech. For…
March 25, 2022
The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK 15,2 M. The error has been discovered in connection with the finalization of the Annual…
February 9, 2022
FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular proved to be a busy period, with continued strong development with all the prioritized projects in our portfolio. Tasquinimod Clinical…
February 9, 2022
Lund, February 9, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in treatment of myelofibrosis (MF).…